文献速递浆细胞疾病淋巴瘤

抑制IDH2增强血液系统恶性肿瘤对蛋白酶体抑制剂的反应

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
PubMed 文献 · Blood · 2018-11-19

研究通过功能筛选发现IDH2是蛋白酶体抑制剂的合成致死靶点,IDH2抑制剂AGI-6780与卡非佐米联用可在多发性骨髓瘤、套细胞淋巴瘤和伯基特淋巴瘤细胞系中产生协同细胞毒性,并增加原代CD138+细胞死亡,机制涉及NAMPT/SIRT3/IDH2通路抑制。

要点

  • IDH2被鉴定为与卡非佐米合成致死的候选靶点。
  • AGI-6780与FDA批准蛋白酶体抑制剂联用触发协同细胞毒性。
  • NAMPT/SIRT3/IDH2通路抑制增强蛋白酶体抑制剂疗效。

核心结论

  • NAMPT/SIRT3/IDH2通路抑制增强蛋白酶体抑制剂的治疗疗效。

研究设计与样本

  • 利用靶向癌症驱动基因的短发夹RNA文库在多发性骨髓瘤细胞系中进行功能筛选。

主要发现

  • IDH2被鉴定为与卡非佐米合成致死的顶级候选靶点。
  • FDA批准的蛋白酶体抑制剂与AGI-6780联用在多发性骨髓瘤、套细胞淋巴瘤和伯基特淋巴瘤细胞系中触发协同细胞毒性。
  • 卡非佐米/AGI-6780处理增加多发性骨髓瘤患者原代CD138+细胞死亡,并对外周血单个核细胞和骨髓来源基质细胞表现出有利的细胞毒性特征。
  • 卡非佐米/AGI-6780联用显著降低三羧酸循环活性和腺苷三磷酸水平,为增强IDH2酶抑制的结果。
  • 卡非佐米处理降低烟酰胺磷酸核糖转移酶(NAMPT)表达,从而通过NAD+依赖性去乙酰化酶SIRT3限制IDH2激活。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibitors (PI) are extensively used for the therapy of multiple myeloma (MM) and mantle cell lymphoma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. Here, to identify targets that synergize with PI, we carried out a functional screening in MM cell lines using a short hairpin RNA library against cancer driver genes. Isocitrate dehydrogenase 2 (IDH2) was identified as a top candidate, showing a synthetic lethal activity with the PI carfilzomib (CFZ). Combinations of US Food and Drug Administration-approved PI with a pharmacological IDH2 inhibitor (AGI-6780) triggered synergistic cytotoxicity in MM, mantle cell lymphoma, and Burkitt lymphoma cell lines. CFZ/AGI-6780 treatment increased death of primary CD138+ cells from MM patients and exhibited a favorable cytotoxicity profile toward peripheral blood mononuclear cells and bone marrow-derived stromal cells. Mechanistically, the CFZ/AGI-6780 combination significantly decreased tricarboxylic acid cycle activity and adenosine triphosphate levels as a consequence of enhanced IDH2 enzymatic inhibition. Specifically, CFZ treatment reduced the expression of nicotinamide phosphoribosyltransferase (NAMPT), thus limiting IDH2 activation through the NAD+-dependent deacetylase SIRT3. Consistently, combination of CFZ with either NAMPT or SIRT3 inhibitors impaired IDH2 activity and increased MM cell death. Finally, inducible IDH2 knockdown enhanced the therapeutic efficacy of CFZ in a subcutaneous xenograft model of MM, resulting in inhibition of tumor progression and extended survival. Taken together, these findings indicate that NAMPT/SIRT3/IDH2 pathway inhibition enhances the therapeutic efficacy of PI, thus providing compelling evidence for treatments with lower and less toxic doses and broadening the application of PI to other malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bergaggio E, Riganti C, Garaffo G, et al. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood. 2018. PMID: 30455381. doi:10.1182/blood-2018-05-850826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。